NCT07648693 Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
| NCT ID | NCT07648693 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Resonova (Shanghai) Medtech Limited |
| Condition | Transcatheter Aortic Valve Replacement (TAVR) |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2025-10-31 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2025-10-31 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, multi-center, randomized controlled study. The goal of the study is to assess the safety and effectiveness of the Resonova® CHORDS® Cerebral Protection System in capturing and removing embolic debris during Transcatheter Aortic Valve Replacement (TAVR). A total of 240 eligible participants will be enrolled and randomized in a 1:1 ratio to undergo TAVR either with the CHORDS® Cerebral Protection System (Test group) or the Sentinel System (Control group).All the participants will be followed up at 30 days and 90 days post-procedure.
Eligibility Criteria
Inclusion Criteria: * Male or non-pregnant female, ≥18 years * Patients with symptomatic severe aortic stenosis who are scheduled to undergo TAVR with commercialized transcatheter aortic valve system. * Compatible left common carotid artery (6.5-10 mm) and brachiocephalic artery (9-15mm) diameters without significant stenosis (\> 70%) * Patients who are able to understand the study objectives, voluntarily participate, sign the informed consent form, and are willing to undergo required examinations and clinical follow-up. Exclusion Criteria: General * Contraindications to MRI, or planned implantation of an MRI-incompatible device at the index procedure, or planned implantation of an MRI-incompatible pacemaker or defibrillator within 30 days post-procedure. * Acute myocardial infarction ≤ 30 days before the intended treatment * Pure aortic regurgitation * Pre-existing prosthetic aortic valve * Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation * Contraindication to antiplatelet and/or anticoagulant therapy, nitinol , or contrast media, or refusal to receive blood transfusions * Vulnerable populations, including those unable to adequately understand the trial, those potentially subject to undue influence or coercion, those unable to complete the informed consent process, and those with severe disabling dementia or cognitive impairment Anatomic * Vasculature (ie, right radial/brachial artery, carotid artery) precluding the device access * Patients whose brachiocephalic or left carotid artery reveals significant stenosis（\>70%）, ectasia, dissection, or aneurysm at the ostium or within 3 cm of the ostium
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07648693 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Transcatheter Aortic Valve Replacement (TAVR). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07648693 currently recruiting?
Yes, NCT07648693 is actively recruiting participants. Contact the research team at j.xu@resonmed.com for enrollment information.
Where is the NCT07648693 trial being conducted?
This trial is being conducted at Bengbu, China, Hefei, China, Beijing, China, Chongqing, China and 11 additional locations.
Who is sponsoring the NCT07648693 clinical trial?
NCT07648693 is sponsored by Resonova (Shanghai) Medtech Limited. The trial plans to enroll 240 participants.